Carregant...
Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma
OBJECTIVES: The incidence of metastatic renal cell cancer (mRCC) is rising. To date, Interleukin-2 (IL-2) is the only treatment offering a complete response rate for mRCC. We wish to test the hypothesis that the combination of restricted availability and expense associated with IL-2 administration r...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2864345/ https://ncbi.nlm.nih.gov/pubmed/19070518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2008.09.022 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|